Swing Trade Ideas

🏃🚀✅  VCIG high 1.72, up 72%  🚀 

🏃🚀✅  BYND 1.43 , UP 61% 🚀 

🏃🚀✅  SPRC 3.62 , UP 32% 🚀  

🏃🚀✅  SBET 3.24 , UP 30% 🚀  

🏃🚀✅  VERO 3.63 , UP 73% 🚀  

🏃🚀✅  BYKI  1.37 , UP 110% 🚀  

🏃🚀✅  SCNX 2.34, UP 66% 🚀  

 ✅ GNSS potential entry: $2.12 – $2.17

🎯 PT1: $2.40 – $2.80, 🎯 PT2: $2.90 – $3.50, 🎯 PT3: $3.60 – $3.90

🚫 Stop: Below $2.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 another rinse and repeat, recently announced $1M follow-on order from nuclear energy operator, also recently entered strategic partnership with Julie Parker Communications, recently received $9M order from teh US Army for its long range acoustic, also recently secured $1.7M follow-on LRAD order from southeast Asia military as part of multi-year program for long range communication device systems, company provides protective communications solutions, serving the federal, state/local government (SLED), enterprise critical infrastructure , globally in >100 countries and all 50 US states, Roth MKM buy rating 

 ✅ BNBX entry: $2.30 – $2.40

🎯 PT1: $2.70 – $3.2, 🎯 PT2: $3.30 – $3.8, 🎯 PT3: $3.90 – $4.40

🚫 Stop: Below $2.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 back to support from recent high above 6, formerly Applied DNA Sciences $APDN , company focuses in digital asset treasury services, also offers DNA/RNA manufacturing and molecular diagnostic services 

 ✅ BYND potential entry: $0.80 – $0.85

🎯 PT1: $1.20 – $1.90, 🎯 PT2: $2.05 – $3.80, 🎯 PT3: $3.90 – $4.50

🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 back to support from recently high above 7, recently launched latest Beyond Burger at Hard Rock Cafe and introduced Beyond Beef at retailers across Canada, company produces plant-based meat alternatives, does have mixed shelf, be mindful on next spike 

✅ CIGL potential entry: $1.60 – $1.70

🎯 PT1: $2.00 – $2.60, 🎯 PT2: $2.70 – $3.30, 🎯 PT3: $3.40 – $3.90

🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 recently acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients, 

 ✅ ASST potential entry: $1.05–$1.10
🎯 PT1: $1.50–$1.90, 🎯 PT2: $2.00–$2.60, 🎯 PT3: $2.70–$3.40
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
recently announced $1.33 per share dividend on SATA stock, recently completed merger with Semler Scientific, recent 13F filing discloses Candada'based pension fund acquires more than 5% shares, millions of dollar's worth of $BTC.X focused treasury firm ASST, founded by Vivek Ramaswamy, recent IPO 

 ✅ LGPS potential entry: $1.00
🎯 PT1: $1.40–$1.90, 🎯 PT2: $2.00–$2.50, 🎯 PT3: $2.80–$3.00
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently announced shares available for trading through Mitsubishi UFJ Morgan Stanley Securities, recently announced joint venture with Inmark Global, previously approved $543k share repurchased program to buy up to 1.087M shares through June 2026, company focuses in real-estate management & development 

 ✅ SLNH potential entry: $1.35–$1.45

🎯 PT1: $1.60 – $2.40, 🎯 PT2: $2.50 – $2.8, 🎯 PT3: $2.90 – $3.50

🚫 Stop: Below $1.20 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
previously surpassed 1-Gigawatt Milestone in clean data centers with new Texas Solar and wind projects, expanded partnership with Galaxy Digital with 48 MW $BIT.X Mining deployment at Texas Project, also recently expanded with new $20M funding and project Kati Construction launch, a wind-powered data center, with construction expected to begin Q3 2025, company specializing in developing renewable-powered data centers for compute-intensive applications like $BIT.X mining and AL workloads, 

✅ WWR potential entry $0.80–$0.85

🎯 PT1: $1.10–$1.80, 🎯 PT2: $2.00–$2.50, 🎯 PT3: $2.60–$3.70

🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 Company focuses on battery-grade natural graphite and associated critical materials including vanadium for clean energy/battery storage market, HW Wainwright price target $1.75 

✅ MAIA entry: $0.85

🎯 PT1: $1.20 – $1.60, 🎯 PT2: $1.70 – $2.50, 🎯 PT3: $2.60 – $3.30

⛔ Stop: Below $0.85 or 2%–5% or daily max risk per trade

🟡 Risk Level: Medium | Catalyst-Driven | Technical Setup
back to 52wk low from recent high, recently secured European patent for cancer therapy, received FDA fast track designation for Ateganosie for its treatment of non-small cell lung cancer, recently announced agreement with ROCHE for cancer therapies, recently announced positive phase 2 clinical trial, Noble Financial price target $14, company focuses on novel telomere-targeting drug called THIO (ateganosine), aimed at telemerase-positive cancers, especially non-small cell lunch cancer (NSCLC) and pediatric high-trade gliomas, operates multiple clinical-stage programs with a team based in Chicago, upcoming catalysts: 1) update clinical data on efficacy/safety for phase 2 

✅ GETY entry: $1.30 – $1.40

🎯 PT1: $1.60 – $2.00, 🎯 PT2: $2.05 – $2.50, 🎯 PT3: $2.60 – $3.70

⛔ Stop: Below $1.25 or 2%–5% or daily max risk per trade

🔴 Risk Level: High | Fast moving | Technical Setup

 near 52wk low from recent high above 3,  company is a visual content focusing supplying licensed images, videos, audio and other digital medial to businesses, media companies, previously announced merger with Shutterstock, expected to close by 2025, Wedbush buy rating, 

 ✅ EPWK entry: $1.50 – $1.60
🎯 PT1: $1.80 – $2.20, 🎯 PT2: $2.30 – $2.80, 🎯 PT3: $2.90 – $3.80
⛔ Stop: Below $1.20 or 2%–5% or daily max risk per trade
🔴 Risk Level: High | Fast moving | Technical Setup
recent 1/40 reverse split, recently launched of bilingual e-commerce platform, company is an online marketplace focuses in creative services/talent platform, 

 ✅ APM entry: $1.45 – $1.50
🎯 PT1: $1.80 – $2.30, 🎯 PT2: $2.40 – $2.90, 🎯 PT3: $3.00 – $3.50
⛔ Stop: Below $1.20 or 2%–5% or daily max risk per trade
🟡 Risk Level: Medium | Catalyst-Driven | Technical Setup 

 recently announced NASDAQ compliance, recently announced merger with DiamiR Bioscience, aiming to advance brain health solutions, expected to close Q4 2025, company focuses on targeting disease with unmet medical needs in oncology and infectious diseases. 

 ✅ CAPS entry: $0.80 – $0.82
🎯 PT1: $1.20 – $1.60,🎯 PT2: $1.70 – $2.4,🎯 PT3: $2.50 – $2.90
⛔ Stop: Below $0.75 or 2%–5% or daily max risk per trade
🟡 Risk Level: Medium | Catalyst-Driven | Technical Setup
back to 52wk low from recent high, recently completed acquisition of Caroline Stone, began integration and expanded southeast presence, previously secured $3m for strategic acquisition, company focuses on developing peptide-based therapies for cardiovascular conditions, company DOES have active mixed shelf recently filed, be mindful on next big spike 

 FLD entry: $2.95 – $3.00
🎯 PT1: $3.20 – $3.80, 🎯 PT2: $4.00 – $4.8, 🎯 PT3: $5.00 – $5.50
⛔ Stop: Below $2.80 or 2%–5% or daily max risk per trade
🔴 Risk Level: High | Fast Moving | Technical Setup 

 back to near 52wk low from recent high, company operates a bitcoin-financial-services platform that enables consumers to earn, save, and use $BTC.X via consumer financial products, recently partnered with Steak n' Shake for BTC.X promotion, CEO previously announced wanting BTC.X gift card to be available in holiday season, Cantor Fitzgerald price target $6.50, does have mixed shelf, be mindful on next spike, 

 ✅ VTAK entry: $1.75 – $1.80
🎯 PT1: $2.40 – $2.80, 🎯 PT2: $3.00 – $3.60, 🎯 PT3: $3.70 – $4.30
⛔ Stop: below $1.75 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical setup
back to near 52wk low from recent high above $4.30, small float, recently entered distribution agreement with FuMedica, and announced two patents to be issued by USPTO, previously received Approval for LockeT in the United Kingdom, announced introduction of LockeT product line into Italy, company specializes in medical device based in US, two main products: VIVO system is a non-invasive, ED cardiac mapping system that integrates ECG and imaging data to help localize ventricular arrhythmia origins before procedures, the other is LockeT device, a suture retention tool designed to optimize vascular closure after percutaneous procedures, aiming to speed up hemostasis and patient recovery,  does have mixed shelf, 

 ✅ SPRC entry: $2.40 – $2.60
🎯 PT1: $2.80 – $3.40, 🎯 PT2: $3.50 – $3.90, 🎯 PT3: $4.00 – $4.70
⛔ Stop: below $2.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high above 8, recently Launched Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery, company focuses on developing therapies for disorders of the central nervous system , recent 1/21 reverse split, 

 ✅ UPC entry: $3.50 – $3.60
🎯 PT1: $4.00 – $4.40, 🎯 PT2: $4.50 – $5.20, 🎯 PT3: $5.30 – $6.00

⛔ Stop: below $3.30 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup
back to support from recent high above $10, company focuses on production and distribution of health-care products, previous 1/40 reverse split, 

✅ TBH potential entry: $1.02 – $1.05
🎯 PT1: $1.40 – $1.80, 🎯 PT2: $2.00 – $2.60, 🎯 PT3: $2.70 – $3.50

⛔ Stop: Below $0.90 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-driven | Technical setup

 back to support from recent high above 2, merging with House of Doge in a reverse takeover transaction, expected to complete early 2026,  recently announced $4M investment in CleanCore's $DOGE.X treasury model, recently launched secure digital assets platform for NIL initiative, recently featured on RedChip small stocks, big money show on Bloomberg TV, Zacks Small-cap research price target $4.40, company operates a Gen-Z focused esports and gaming platform 

 ✅ INTS potential entry: $0.40 – $0.45
🎯 PT1: $0.80 – $1.20, 🎯 PT2: $1.30 – $1.80, 🎯 PT3: $1.90 – $2.40
🚫 Stop: Below $0.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recent drop on offering news price $0.80, recently announced phase 1/2 data for solid tumors asset, company focuses on developing intratumoral cancer therapies, does have an active approved reverse split, however, company currently in compliance 

 ✅ XTKG entry: $1.55 – $1.65
🎯 PT1: $2.00 – $2.40, 🎯 PT2: $2.50 – $3.2, 🎯 PT3: $3.30 – $3.80
🚫 Stop: Below $1.30 or 2%–5% or daily max risk per trade 

 🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently acquired creation intelligent to boost gaming portfolio, company focuses on digital solutions and technology, operating across four primary segments: digital technologies, crypto mining, renewable energy, and Argi-tech, DOES have active mixed shelf, be mindful on next spike 

 ✅ $AIM potential entry: $1.50 – $1.60
🎯 PT1: $1.90 – $2.30 🎯 PT2: $2.40 – $2.80 🎯 PT3: $3.00 – $3.40
🚫 Stop: Below $1.45 or 2%–5% or daily max risk per trade
🟡 Risk Level: Medium | Catalyst-Driven | Technical Setup
back to 52wk low from recent offering price $0.91, recently announced positive data at cancer meeting, company seeking FDA meeting for DS0101 approval for head and neck cancer, company develops precision cancer immunotherapies using its proprietary Versamune lipid nanoparticle platform, which stimulates strong T-cell activation to target disease antigens, current pipeline: Versamune HPV Combines with pembrolizumab (Keytruda) to treat HPV16-positive cancers like head & neck, cervical, anal, vagina, and vulvar cancers, and PDS01ADC to treat colorectal cancer, HC Wainwright price target $13 

 ✅ $PDSB entry: $0.85 – $0.95
🎯 PT1: $1.20 – $1.70 🎯 PT2: $1.80 – $2.40 🎯 PT3: $2.50 – $2.80
🚫 Stop: Below $0.80 or 2%–5% or daily max risk per trade
🟡 Risk Level: Medium | Catalyst-Driven | Technical Setup 

 back to 52wk low  from recent high above 2.50, recently announced grant of European patent covering Ampligen, recent offering price at $4.0, ultra small float <1m,  upcoming catalyst: 1) top line data for DURIPANIC for pancreatic cancer expected Q2-Q3 2026, Ascendiant reaffirms buy rating price target $24, Maxim Group buy rating, CEO Thomas Equels recent purchased at $8.70/share 6/13 and $7.70 share 6/16 

 ✅ $CJET potential entry: $2.40 – $2.50
🎯 PT1: $2.80 – $3.30 🎯 PT2: $3.40 – $3.90 🎯 PT3: $4.00 – $4.60
🚫 Stop: Below $2.40 or 2% – 5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
CJET potential 2.40/.50, stop if below 2.40 or daily max risk per trade @ recent 1/100 reverse split , recently announced MOU for expanded private placement up to $1B following strong investor demand, recently acquired 80% stake in Too Express Group Inc through $40 M equity investment, company focuses in the designing, production, sale and after sale service of new energy vehicles and vehicle parts, 

 ✅ $IFRX entry $1.70–$1.80
🎯 PT1 $1.80–$2.50 🎯 PT2 $2.60–$3.30 🎯 PT3 $3.40–$3.80
🚫 Stop below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level 🟡 Medium | Catalyst-Driven | Technical Setup 

 IFRX Potential  swing 1.40/.50, stop if below 1 or daily max risk per trade  @  recently announced positive phase 2a results of INF904 in treating Hidradenitis Suppurativa and Chronic Spontaneous Urticaria, company focuses on development of complements C5a system (anti-C5a monoclonal antibody vilobelimab and oral C5aR inhibitor INF904) for inflammatory and autoimmune disease such as Hidradenitis Suppurativa and chronic spontaneous Urticaria,  Lucid Capital raised price target to $24 from $3, Guddenheim raised price target to $22 from $10, Leerink Partners buy rating, H.C Wainwright buy rating, price target $6, 

 ✅ $LGCL potential entry $2.65 – $2.75
🎯 PT1: $3.00 – $3.60 🎯 PT2: $3.70 – $4.20 🎯 PT3: $4.30 – $4.80
🚫 Stop: Below $2.50 or 2% – 5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
LGCL potential swing 2.60/.70, stop if below 2.50 or daily max risk per trade @ back to support from recent high,  Recently regained compliance, granted US patent titled "Unified platform of an artificial intelligence base test generator and test training system, recently 1/40 reverse split, company focused on AI technology-driven platform-as-a-service company with operations in human resources and insurance industry verticals 

 ✅ $TMDE entry $.65–$.70
🎯 PT1 $.95–$1.30 🎯 PT2 $1.50–$1.80 🎯 PT3 $2.00–$2.60
🚫 Stop below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level 🟡 Medium | Catalyst-Driven | Technical Setup 

  TMDE another rinse and repeat, potential swing .65/.70, stop if below .65 or daily max risk per trade @here back to support from recent high above 4.35, small float, recently announced partnership with Double Corporate for Green Bioenergy Expansion, previously announced expansion into oil waste collection, company specializes in the supply and marketing of marine gas oil and marine fuel oil based in Malaysia and Singapore,, also offers ship management services and vessels chartering. recent IPO 

 ✅ PHIO
🎯 Potential Entry: $1.35 – $1.45
🎯 PT1: $1.70 – $2.30 🎯 PT2: $2.40 – $2.90 🎯 PT3: $3.00 – $3.60
🚫 Potential Stop: Below $1.10 or 2 % – 5 % or daily max risk per trade
Risk Level: Medium | Catalyst-Driven | Technical Setup
back to near key support from recent high above 4, will present recent clinical data on phase 1b  INSASYL PH-762, an siRNA-based therapeutic at the 40th Annual Meeting of the Society for Immunotherapy of Cancer on 11/8/2025 at the Gaylord National Resort and Convention Center in National Harbor, Maryland, recently reported 100% tumor clearance in final dose group of skin cancer trial , previously announced partnership with U.S Manufacturer for development of lead compound PH-762, targeting PD-1 gene silencing, for treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma HC Wainwright price target $14, does have mixed shelf, be mindful on next spike 

 ✅ STEX
🎯 Entry: $4.30 – $4.40
🎯 PT1: $4.80 – $5.50 🎯 PT2: $5.60 – $6.00 🎯 PT3: $6.10 – $6.80
🚫 Stop: Below $4.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 formerly $BSGM) back to support from recent high above 14, recently secured $25M financing for Gold Strategy, also partnership with Chainlink to boost tokenization infrastructure, company focus on bringing physical commodities (especially goal) and other assets on-chain, creating digital/crypto adjacent financial product 

 ✅  $BYND entry: $1.10 – $1.20
🎯 PT1: $1.50 – $1.90 🎯 PT2: $2.05 – $3.80 🎯 PT3: $3.90 – $4.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
back to support from recently high above 7, recently launched latest Beyond Burger at Hard Rock Cafe and introduced Beyond Beef at retailers across Canada, company produces plant-based meat alternatives, does have mixed shelf, be mindful on next spike 

 ✅ $STEC entry: $1.00
🎯 PT1: $1.30 – $1.80 🎯 PT2: $1.90 – $2.50 🎯 PT3: $2.60 – $3.00
🚫 Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back to consolidation form recent high near $3, recently regained Nasdaq compliance, company focuses on consumer technology, healthcare and enterprise 

 ✅  $HKD potential entry: $1.80 – $1.90
🎯 Potential PT1: $2.30 – $2.70 🎯 PT2: $2.80 – $3.50 🎯 PT3: $3.60 – $4.20
🚫 Potential Stop: Below $1.70 or 2% – 5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
back to consolidation from recent high above 5, recently announced to open second L'OFFICIEL COFFEE at Macau's City of dreams with $TGE and in talks to buy 150-room hotel in New York City, a holding company that operates via subsidiaries in digital solutions, media and entertainment 

 ✅  $MRM entry: $1.85 – $1.95
🎯 PT1: $2.40 – $2.80 🎯 PT2: $2.90 – $3.40 🎯 PT3: $3.50 – $3.90
🚫 Stop: Below $1.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back support from recent high above 4, recently announced launching new treasury strategy using cryptocurrency, previously announced more than 10,000 people received verified World IDS at $MRM locations, recent partnership announcement with World, co-founded by Sam Altman to double deployment of Orb Human authentication device across Japan, company is a Japan-based holistic healthcare, does have mixed shelf, be mindful on next spik

✅ TELO potential entry: $1.40 – $1.50

🎯 Potential PT1: $1.60 – $1.90 🎯 PT2: $2.00 – $2.50 🎯 PT3: $2.60 – $2.80

🚫 Potential Stop: Below $1.10 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
 back to near 52 weak low from recent high,  recently announced positive  preclinical data data for Telonmir-1  in breast cancer, company focuses on reversing biological aging and degenerative diseases, analyst price target $15, earnings 11/12 

✅ XTLB potential entry: $1.00

🎯 Potential PT1: $1.20 – $1.60 🎯 PT2: $1.70 – $2.40 🎯 PT3: $2.50 – $3.30

🚫 Potential Stop: Below $0.85 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 back to near 52wk low from recent high above 2.50, company focuses on acquisition and development targeting autoimmune diseases